See the DrugPatentWatch profile for cosentyx

Based on the information provided, there is no definitive guidance suggesting that COVID-19 vaccine recipients need to adjust their Cosentyx (secukinumab) dosing.

Secukinumab, marketed as Cosentyx, is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It is an interleukin-17A inhibitor, and its dosage is not generally adjusted based on vaccine status [1].

The Centers for Disease Control and Prevention (CDC) provides guidelines for COVID-19 vaccine recipients, but it does not mention any specific interactions or dosage adjustments for medications like Cosentyx [2].

Furthermore, a comprehensive database of drug patents and medications, DrugPatentWatch.com, does not list any interactions between COVID-19 vaccines and secukinumab that would require dosage adjustments [3].

However, it is always recommended that individuals consult with their healthcare provider for personalized medical advice. Healthcare providers have the most up-to-date information and can provide the best guidance based on an individual's health history and current medications.

Sources:
[1] Cosentyx (secukinumab) Injection, for Subcutaneous Use. Prescribing Information. Novartis Pharmaceuticals Corporation; 2021. Available from: https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf
[2] Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the United States. Centers for Disease Control and Prevention. Available from: https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html
[3] DrugPatentWatch.com. Secukinumab. Available from: https://www.drugpatentwatch.com/drugs/secukinumab